NCCN Best Practices Committee
Drug Shortage Follow-Up Survey Results

Publication Date: October 5, 2023

Survey data collected from September 6, 2023 – September 27, 2023
Drug Shortage Follow Up

Is your center still experiencing a shortage of carboplatin?

(N=29)

Yes 72%

No 24%

Not applicable, never experienced a shortage 4%

Comments:

• Across our enterprise, supply is recovering but we are still enacting our drug shortage SOP.
• Able to obtain, just not at full capacity.
• We still are getting intermittent shipments. Supply is better but not back to normal.
• Limited market availability for the last 4 months.
• We are on allocation from manufacturers.
• We have sufficient supply to treat patients, however, we never know if our back orders are going to be filled. It’s still living paycheck to paycheck.
• Supply pressures still impacting us but not as severely as before.
• Continue to track inventory but maintaining supply.
Drug Shortage Follow Up

Is your center able to treat all patients who are currently receiving a carboplatin-containing regimen according to the intended dose and schedule?

\((N=21)\)

Comments:

- We access our stock constantly and have barely been getting by week by week.
- We have had an allocation framework that has progressively expanded over time. More recently, due to improved supply, this framework has been suspended. However, we continue to monitor drug utilization and supply closely, and it is uncertain if we may need to revert back to a tiered allocation framework in the future.
Drug Shortage Follow Up

Has your center received any indication from your manufacturers/suppliers when carboplatin will be readily available?  
(N=21)

- Yes: 38%  
- No: 62%

Comments:
- We receive updates from manufacturers/wholesaler on allocations/supplies that will be shipped to us.
- No anticipated date, additional releases from some. Others readily available.
- Information (available date) not historically reliable.
- No specifics.
Drug Shortage Follow Up

Is your center still experiencing a shortage of cisplatin?

(N=29)

- Yes: 59%
- No: 38%
- Not applicable, never experienced a shortage: 3%

Comments:
- Limited market availability during the last 4 months.
- Able to get some supply, but not necessarily enough for new patients.
- Same as previous—while supplies were less than usual, we always had ample supply to treat patients.
- Continue to track inventory.
Drug Shortage Follow Up

Is your center able to treat all patients who are currently receiving a cisplatin-containing regimen according to the intended dose and schedule?

(N=17)

- **Yes**: 88%
- **Some current patients, but not all**: 12%

Comments:
- Similar to carboplatin - drug shortage SOP in place.
- Like carboplatin, we get supplies in weekly that barely cover our usage. But so far, we have not restricted usage beyond our current regular guidelines.
- Based on drug shortage plan at reduced dose, not back to normal process.
Drug Shortage Follow Up

Has your center received any indication from your manufacturers/suppliers when cisplatin will be readily available?  
(N=17)

- Yes 29%
- No 71%

Comments:
- There have been general timeframes but no specific dates.
- Improving market availability.
- Yes, however the dates are continually being extended.
- Like carboplatin, we are in constant communication with our wholesalers and manufacturers to get updates on current supply. No long-term info as to when shortage will resolve.
Drug Shortage Follow Up

Has re-obtaining prior-authorizations because of modified treatment plans (due to shortages) resulted in treatment delay?

(N=26)

No
100%
Drug Shortage Follow Up

Have any of your center's modified treatment plans (due to oncology drug shortages) been denied by payers?

(N=25)
Drug Shortage Follow Up

Please indicate if there are other drugs in short supply at your center.

(N=29)

- Methotrexate: 66%
- 5-Fluorouracil: 55%
- Fludarabine: 45%
- Hydrocortisone: 41%
- Dacarbazine: 28%
- Liposomal Doxorubicin (Doxil): 24%
- Vinblastine: 21%
- Capecitabine: 14%
- Decitabine: 14%
- Docetaxel: 10%
- Paclitaxel: 10%
- Amifostine: 7%
- Azacitidine: 7%
- None: 14%
- Other (please specify): 24%

© National Comprehensive Cancer Network, Inc. 2023, All rights reserved.